Dr. Tom Ingallinera is Pii’s technical liaison between the Business Development team, Project Management, Operations, and our valued Partners. Tom has over 40 years of experience in pharmaceutical development, with particular expertise in parenteral dosage forms. He has advised on product development programs across the continuum, from pre-formulation through commercial production. Tom has worked at several leading pharmaceutical companies including BioCryst Pharmaceuticals, Parenta Pharmaceuticals, AAI Pharma, Genzyme, Burroughs Welcome, and A.H. Robins. Dr. Ingallinera has a B.S. in Pharmacy with a Ph.D. in Pharmaceutics from Virginia Commonwealth University.
Bryan Braxton joined Pii in October 2018 as Senior Director of Aseptic R&D. Bryan has 30 years of experience in the pharmaceutical industry.
Bryan held roles of increasing responsibility in sterile products at both Unither, AMRI, Pfizer, Abbott, and Glaxo, in the areas of Formulation Development, Process Transfer, Quality by Design, Technical Services, Contract Services, and Project Management.
Bryan earned a Ph.D. in Pharmaceutical Chemistry from the University of Kansas and is a registered pharmacist.
Dr. Sundeep Sethia joined Pii in September 2018 as Senior Director of Pharmaceutical R&D. He has over 15 years of experience in the pharmaceutical industry.
Dr. Sethia formerly served as the Director of Pharmaceutical R&D at Amneal Pharmaceuticals. Prior to Amneal, he held positions of increasing responsibility at both Teva and Barr Laboratories in R&D. His expertise is in drug development across a broad range of therapeutic areas and dosage forms. He has a proven track record in generic drug development and approvals.
Dr. Sethia received his Ph.D. in Pharmaceutical Sciences from St. John’s University, NY. He earned a Master’s and a Bachelor’s degree in Biotechnology and Pharmacy, respectively from Jadavpur University in India. He has co-authored various peer-reviewed scientific publications and patents/patent applications.
Dr. Gene Mirkin joined Pii in 2003 as an Analytical R&D Senior Chemist. Since then he has quickly gained responsibility as he rose to Team Leader, Method Development in 2005, Associate director, Method Development in 2012 to his current role as Director/Senior Director, Analytical R&D in 2018.
Prior to joining Pii, he served as a Senior Chemist at UPM Pharmaceuticals and an Analytical Method Development Chemist at CelsisIVT. Dr. Mirkin’s decades of experience in analytical techniques, instrumentation and chromatography as well as his extensive expertise in method development and validation make him a critical resource in the development of drugs and technologies.
Dr. Mirkin received his B.S. in Chemistry/Biology from the University of Maryland.